Hyabest® (J) - Recent Research supports efficacy for Knee Osteoarthritis

TOKYO― Q.P. Corporation has developed an innovative hyaluronic acid specially designed for those with knee osteoarthritis - Hyabest®(J). For this product, they recently obtained 8-week clinical data based on a WOMAC randomized double-blind placebo-controlled clinical trial, which followed a successful result obtained earlier from a similar trial in Japan (JKOM).

The trial results indicated that Hyabest®(J) , at both 200mg/day dosage and 100mg/day dosage, contributed to significant improvement in all scores of WOMAC. Furthermore, the researchers did an exploratory analysis for the subgroup (moderate-to-severe condition subjects). Efficacy for this group of people was noticeable, according to Q.P. Corporation.

The company is also explaining the suspected mechanism of action for Hyabest®(J) and has made a noteworthy trial determining how Hyabest®(J) could potentially retard the advancement of osteoarthritis .

This comprehensive information will be shown to visitors to the Q.P. Corporation booth at Natural Products Expo West at Anaheim 6-8th March, 2008.

The company is also preparing for the publishing of the results of these studies in an upcoming issue of the Journal of New Remedies and Clinics.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.